Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
NCT04394858Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2021
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in pheochromocytoma, Paraganglioma (PGL), sponsored by National Cancer Institute. Started Mar 2021; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT04394858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04394858.